2月3日周一上午,医药股亚盛医药-B(06855)盘中大涨5.01%,引发市场关注。
据分析,亚盛医药主打血液瘤小分子药物,其核心产品耐立克已在国内获批上市。耐立克是国内首个获批的三代BCR-ABL抑制剂,2024年已纳入国家医保目录,预计2025年销售收入将加速增长,有望实现翻倍增长。另一产品APG-2575国内已递交上市申请,海外III期临床进展顺利。
此外,亚盛医药1月24日在纳斯达克挂牌上市,有助于公司开拓海外市场,未来收入增长可期。分析指出,公司海外市场潜力较大,随着核心产品销售放量及合作款项到账,2025至2026年营收有望大幅增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.